Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects
Open accessPublished version of a preprint
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Only a small fraction of early drug programs progress to the market, due to safety and efficacy failures, despite extensive efforts to predict safety. Characterizing the effect of natural variation in the genes encoding drug targets should present a powerful approach to predict side effects arising from drugging particular proteins. In this retrospective analysis, we report a correlation between the organ systems affected by genetic variation in drug targets and the organ systems in which side effects are observed. Across 1819 drugs and 21 phenotype categories analyzed, drug side effects are more likely to occur in organ systems where there is genetic evidence of a link between the drug target and a phenotype involving that organ system, compared to when there is no such genetic evidence (30.0 vs 19.2%; OR = 1.80). This result suggests that human genetic data should be used to predict safety issues associated with drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F., & Hamosh, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1205 · Cited by 2,691
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations
Denny, J. C., Ritchie, M. D., Basford, M. A., Pulley, J. M., Bastarache, L., Brown-Gentry, K., Wang, D., Masys, D. R., Roden, D. M., & Crawford, D. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq126 · Cited by 1,219
The human phenotype ontology: a tool for annotating and analyzing human hereditary disease
Robinson, P. N., Köhler, S., Bauer, S., Seelow, D., Horn, D., & Mundlos, S. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.09.017 · Cited by 1,034
Research works printed but not linked: 47
- Plenge, R. M. Disciplined approach to drug discovery and early development. Sci. Transl. Med 8, 349ps315 (2016). · DOI · Paper page
- Knowles, J. & Gromo, G. A guide to drug discovery: target selection in drug discovery. Nat. Rev. Drug. Discov. 2, 63–69 (2003). · DOI · Paper page
- Lindsay, M. A. Target discovery. Nat. Rev. Drug. Discov. 2, 831–838 (2003). · DOI · Paper page
- Ma, P. & Zemmel, R. Value of novelty? Nat. Rev. Drug. Discov. 1, 571–572 (2002). · DOI · Paper page
- Duran-Frigola, M. & Aloy, P. Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem. Biol. 20, 594–603 (2013). · DOI
- Duran-Frigola, M., Rossell, D. & Aloy, P. A chemo-centric view of human health and disease. Nat. Commun. 5, 5676 (2014). · DOI
- Juan-Blanco, T., Duran-Frigola, M. & Aloy, P. IntSide: a web server for the chemical and biological examination of drug side effects. Bioinformatics 31, 612–613 (2015). · DOI
- Garcia-Serna, R. & Mestres, J. Anticipating drug side effects by comparative pharmacology. Expert. Opin. Drug. Metab. Toxicol. 6, 1253–1263 (2010). · DOI
- LaBute, M. X. et al. Adverse drug reaction prediction using scores produced by large-scale drug-protein target docking on high-performance computing machines. PLoS. ONE 9, e106298 (2014). · DOI
- Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361–367 (2012). · DOI · Paper page
- Scheiber, J. et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 49, 308–317 (2009). · DOI · Paper page
- Leeson, P. Drug discovery: chemical beauty contest. Nature 481, 455–456 (2012). · DOI · Paper page
- Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001). · DOI · Paper page
- Alfirevic, A. & Pirmohamed, M. Genomics of adverse drug reactions. Trends Pharmacol. Sci. 38, 100–109 (2017). · DOI
- Hauser, A. S. et al. Pharmacogenomics of GPCR drug targets. Cell 172, 41–54 e19 (2018). · DOI · Paper page
- Ferrero, E., Dunham, I. & Sanseau, P. In silico prediction of novel therapeutic targets using gene-disease association data. J. Transl. Med. 15, 182 (2017). · DOI · Paper page
- Kamb, A., Harper, S. & Stefansson, K. Human genetics as a foundation for innovative drug development. Nat. Biotechnol. 31, 975–978 (2013). · DOI
- Dorato, M. A. & Engelhardt, J. A. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul. Toxicol. Pharmacol. 42, 265–274 (2005). · DOI · Paper page
- Knox, C. et al. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res. 39, D1035–D1041 (2011). · DOI · Paper page
- Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014). · DOI · Paper page
- Wishart, D. S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901–D906 (2008). · DOI · Paper page
- Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug. Discov. 16, 19–34 (2017). · DOI · Paper page
- Shen, J., Song, K., Slater, A., Ferrero, E. & Nelson, M. R. STOPGAP: a database for systematic target opportunity assessment by genetic association predictions. Bioinformatics, https://doi.org/10.1093/bioinformatics/btx274 (2017). · DOI
- Begum, T., Ghosh, T. C. & Basak, S. Systematic analyses and prediction of human drug side effect associated proteins from the perspective of protein evolution. Genome Biol. Evol. 9, 337–350 (2017). · DOI
- Diogo, D. et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat. Commun. 9, 4285 (2018). · DOI · Paper page
- Prasad, N. et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? Nephrology 19, 244–250 (2014). · DOI
- Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723–735 (2005). · DOI · Paper page
- Plagnol, V. et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet. 7, e1002216 (2011). · DOI · Paper page
- Caudy, A. A., Reddy, S. T., Chatila, T., Atkinson, J. P. & Verbsky, J. W. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119, 482–487 (2007). · DOI · Paper page
- Madhani, P., Hughes, J. & Ballard, C. G. Cholinesterase inhibitors and the heart in old age. Adv. Psychiatr. Treat. 10, 399–399 (2004). · doi:10.1192/apt.10.5.399
- ADRAC. Cholinesterase inhibitors and cardiac arrhythmias. Australian Adverse Drug Reactions Bulletin 23, 19 (2004).
- den Hoed, M. et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat. Genet. 45, 621–631 (2013). · DOI · Paper page
- Eppinga, R. N. et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat. Genet. 48, 1557–1563 (2016). · DOI
- Masuda, Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer’s disease—from basic research to bedside. Curr. Alzheimer Res. 1, 315–321 (2004). · doi:10.2174/1567205043332009
- Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A. & Hughes, B. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 64, 2387–2397 (2012). · DOI · Paper page
- Arnold, L. M., Chatamra, K., Hirsch, I. & Stoker, M. Safety and efficacy of esreboxetine in patients with fibromyalgia: an 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 32, 1618–1632 (2010). · DOI
- Denolle, T., Pellizzoni, C., Jannuzzo, M. G. & Poggesi, I. Hemodynamic effects of reboxetine in healthy male volunteers. Clin. Pharmacol. Ther. 66, 282–287 (1999). · DOI
- Paczkowski, F. A., Bonisch, H. & Bryan-Lluka, L. J. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter. Pharmacogenetics 12, 165–173 (2002). · DOI
- Mullard, A. Calls grow to tap the gold mine of human genetic knockouts. Nat. Rev. Drug. Discov. 16, 515–518 (2017). · DOI
- Szklarczyk, D. et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 44, D380–D384 (2016). · DOI · Paper page
- Tasneem, A. et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS. ONE 7, e33677 (2012). · DOI · Paper page
- Kohler, S. et al. The human phenotype ontology in 2017. Nucleic Acids Res. 45, D865–D876 (2017). · DOI · Paper page
- McInnes, B. T., Pedersen, T. & Pakhomov, S. V. UMLS-Interface and UMLS-Similarity: open source software for measuring paths and semantic similarity. Amia. Annu. Symp. Proc. 2009, 431–435 (2009).
- Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015). · DOI · Paper page
- Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). · DOI · Paper page
- Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010). · DOI · Paper page
- Tibshirani, R. et al. Strong rules for discarding predictors in lasso-type problems. J. R. Stat. Soc. Ser. B Stat. Methodol. 74, 245–266 (2012). · DOI · Paper page
Cited by
Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants
Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.-H., Richardson, T. G., Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S. G., et al. (2022) · doi:10.1101/2022.06.17.496443 · Cited by 1,833
Self-citationPlasma proteomic associations with genetics and health in the UK Biobank
Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.-H., Richardson, T. G., Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S. G., et al. (2023) · Nature · doi:10.1038/s41586-023-06592-6 · Cited by 1,880
“11 and Supplementary Table 28); (3) common genetic variation has a subtle, but significant, role in inflammasome-mediated innate immune responses (Supplementary Table 29); and (4) large-scale proteogenomics studies can increase the power and availability of genetic instruments for Mendelian randomization, mimicking dr…”
BackgroundSelf-citationKing, E. A., Davis, J. W., & Degner, J. F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008489 · Cited by 649
Stroke genetics informs drug discovery and risk prediction across ancestries
Mishra, A., Malik, R., Hachiya, T., Jürgenson, T., Namba, S., Posner, D. C., Kamanu, F. K., Koido, M., Le Grand, Q., Shi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05165-3 · Cited by 600
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Szustakowski, J. D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P. G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00885-0 · Cited by 401
Self-citation
Metadata
- Authors
- Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D.
- Venue
- Nature Communications
- Published
- 2019-04-05
- Volume
- 10
- Issue
- 1
- Pages
- 1579-1579
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2950070451
- Cited by
- 101
- References
- 21
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-05-08)
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. https://app.cochat.ai/papers/10.1038/s41467-019-09407-3
- The paper
- Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D. (2019). Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nature Communications. https://doi.org/10.1038/s41467-019-09407-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.